256 related articles for article (PubMed ID: 34397539)
21. Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy.
Vaishnav J; Brown E; Sharma K
Prog Cardiovasc Dis; 2024; 82():113-124. PubMed ID: 38246305
[TBL] [Abstract][Full Text] [Related]
22. Evolving landscape in the management of transthyretin amyloidosis.
Hawkins PN; Ando Y; Dispenzeri A; Gonzalez-Duarte A; Adams D; Suhr OB
Ann Med; 2015; 47(8):625-38. PubMed ID: 26611723
[TBL] [Abstract][Full Text] [Related]
23. Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms.
Elliott P; Gundapaneni B; Sultan MB; Ines M; Garcia-Pavia P
Eur J Heart Fail; 2023 Nov; 25(11):2060-2064. PubMed ID: 37434378
[TBL] [Abstract][Full Text] [Related]
24. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M
Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171
[TBL] [Abstract][Full Text] [Related]
25. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
26. Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies.
Warner AL
Pharmacotherapy; 2021 Dec; 41(12):1081-1091. PubMed ID: 34669976
[TBL] [Abstract][Full Text] [Related]
27. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K
Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival in people with transthyretin amyloid cardiomyopathy who took tafamidis: A Plain Language Summary.
Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
Future Cardiol; 2023 Jan; 19(1):7-17. PubMed ID: 36715498
[TBL] [Abstract][Full Text] [Related]
29. Advances in the Treatment of Cardiac Amyloidosis.
Macedo AVS; Schwartzmann PV; de Gusmão BM; Melo MDT; Coelho-Filho OR
Curr Treat Options Oncol; 2020 Apr; 21(5):36. PubMed ID: 32328845
[TBL] [Abstract][Full Text] [Related]
30. The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era.
Martyn T; Saef J; Hussain M; Ives L; Kiang A; Estep JD; Collier P; Starling RC; Cremer PC; Tang WHW; Hanna M; Jaber WA
J Card Fail; 2022 Oct; 28(10):1509-1518. PubMed ID: 35843490
[TBL] [Abstract][Full Text] [Related]
31. Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis.
Benson MD; Dasgupta NR; Monia BP
Neurodegener Dis Manag; 2019 Feb; 9(1):25-30. PubMed ID: 30561247
[TBL] [Abstract][Full Text] [Related]
32. Tafamidis for the treatment of transthyretin amyloidosis.
Lorenzini M; Elliott PM
Future Cardiol; 2019 Mar; 15(2):53-61. PubMed ID: 30767672
[TBL] [Abstract][Full Text] [Related]
33. Exploring Transthyretin Amyloid Cardiomyopathy: A Comprehensive Review of the Disease and Upcoming Treatments.
Jain H; Reddy MMRK; Dey RC; Jain J; Shakhatreh Z; Manandhar S; Neupane P; Waleed MS; Yadav R; Sah BK; Mahawa R
Curr Probl Cardiol; 2024 Jan; 49(1 Pt B):102057. PubMed ID: 37640179
[TBL] [Abstract][Full Text] [Related]
34. Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid.
Hough A; Wearden J; de Almeida K; Kaiser S
Curr Cardiol Rep; 2020 Aug; 22(10):106. PubMed ID: 32770401
[TBL] [Abstract][Full Text] [Related]
35. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
36. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.
Rettl R; Wollenweber T; Duca F; Binder C; Cherouny B; Dachs TM; Camuz Ligios L; Schrutka L; Dalos D; Beitzke D; Loewe C; Badr Eslam R; Kastner J; Hacker M; Bonderman D
Eur Heart J Cardiovasc Imaging; 2023 Jul; 24(8):1019-1030. PubMed ID: 36881774
[TBL] [Abstract][Full Text] [Related]
37. RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis.
Ioannou A; Fontana M; Gillmore JD
BioDrugs; 2023 Mar; 37(2):127-142. PubMed ID: 36795354
[TBL] [Abstract][Full Text] [Related]
38. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
Witteles RM; Bokhari S; Damy T; Elliott PM; Falk RH; Fine NM; Gospodinova M; Obici L; Rapezzi C; Garcia-Pavia P
JACC Heart Fail; 2019 Aug; 7(8):709-716. PubMed ID: 31302046
[TBL] [Abstract][Full Text] [Related]
39. Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials.
Tomasoni D; Bonfioli GB; Aimo A; Adamo M; Canepa M; Inciardi RM; Lombardi CM; Nardi M; Pagnesi M; Riccardi M; Vergaro G; Vizzardi E; Emdin M; Metra M
Front Cardiovasc Med; 2023; 10():1154594. PubMed ID: 37288260
[TBL] [Abstract][Full Text] [Related]
40. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy?
Müller ML; Butler J; Heidecker B
Eur J Heart Fail; 2020 Jan; 22(1):39-53. PubMed ID: 31912620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]